Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Jun 27 2015

Volume: 385

Issue: 9987

Affiliations

[1 ] Division of Infectious Diseases and Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. Electronic address: psax@partners.org.

[2 ] Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.

[3 ] Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

[4 ] Department of HIV Medicine, King's College, Hospital NHS Foundation Trust, London, UK.

[5 ] Orlando Immunology Center, Orlando, FL, USA.

[6 ] Department of Medicine, University of Alabama Birmingham, Birmingham, AL, USA.

[7 ] Department of Medicine, Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK.

[8 ] AIDS Research Consortium of Atlanta, Atlanta, GA, USA.

[9 ] HIV Unit, Infectious Disease Service. Hospital Universitari de Bellvitge, Barcelona, Spain.

[10 ] Hôpital Saint Louis, Paris, France.

[11 ] AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

[12 ] Instituto Dominicano de Estudios Virologicos (IDEV), Santo Domingo, Dominican Republic.

[13 ] Clinique Medicale L'Actuale in Montreal, Montreal, Canada.

[14 ] Unidad de VIH del Hospital Civil de Guadalajara, CUCS, U de G Guadalajara, Mexico.

[15 ] Gordon Crofoot Research, Houston, TX, USA.

[16 ] Gilead Sciences, Foster City, CA, USA.

Article

Publisher Item ID: S0140-6736(15)60616-X

DOI: 10.1016/S0140-6736(15)60616-X

PubMed ID: 25890673

SO-VID: ef37c596-92b8-46fb-80b6-5acb0e33237f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 178

See all cited by

- Version 1